Search
Sutro Biopharma Inc
STROAdd to Watchlist
9.820USD
+0.230+2.40%
Close 11-13 16:00（ET）
162.82MMarket Cap
LossP/E TTM
Sutro Biopharma Inc (STRO) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Sutro Biopharma Inc in the past month.
Buy
4 Strong Buy
9 Buy
0 Hold
1 Sell
0 Strong Sell
Target Price
47.231USD+419.02%
STRO Analyst Recommendation Trends
In the current month, STRO has received 9 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. STRO average Analyst price target in the last month is 47.231.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
3
3
3
2
1
1
9
9
9
9
10
8
7
5
0
0
0
0
0
1
1
3
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
14
14
13
13
14
12
10
10
STRO Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, STRO EPS is projected to reach -1.682 in FY2026Q4, following reported EPS of -1.899 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-3.77
-2.19
-1.91
-1.68
-1.92
Actual
-2.94
-2.33
-1.90
--
--
Surprise
+21.99%
-5.99%
+0.64%
--
--
FAQs
What is Sutro Biopharma Inc's expected revenue for the next quarter?
Sutro Biopharma Inc's expected revenue is 11.58M.
What is Sutro Biopharma Inc's price target?
Analysts forecast that Sutro Biopharma Inc's price target is USD 47.23, with the highest forecast at USD 61.00 and the lowest forecast at USD 10.00.
How have Sutro Biopharma IncSTRO's recent earnings per share performed?
The market expectation was USD -1.90, while Sutro Biopharma IncSTRO's earnings per share (EPS) for the previous quarter was USD -2.33. EPS for the next quarter is expected at USD -1.68.
What is the analyst rating for Sutro Biopharma Inc?
Based on the ratings of Sutro Biopharma Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.